

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)

12 January 2017

# PRIMA BIOMED COMMENCES RECRUITMENT FOR SECOND COHORT OF MELANOMA TRIAL

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ("Prima" or the "Company") today announced that the first patient has been dosed for the second cohort of its clinical trial program for IMP321 in combination with KEYTRUDA® being conducted in Australia. The second cohort will recruit up to six patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA.

Interim data from the first patient cohort released in December 2016 indicate IMP321 is safe and well tolerated. On the basis of this safety data, the Data Safety Monitoring Board (DSMB) gave approval for the second cohort to commence.

TACTI-mel (<u>Two ACT</u>ive Immunotherapeutics in <u>mel</u>anoma) is a multicentre, open label, Phase I study in which patients with unresectable or metastatic melanoma will be dosed with IMP321 in combination with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA). The study will evaluate safety as the primary endpoint and anti-tumour activity and the immune response to the combination as secondary endpoints.

#### **About IMP321**

IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.

#### **About Prima BioMed**

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321 is a soluble LAG-3Ig fusion protein and an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic

melanoma termed TACTI-mel (clinicaltrials.gov identifier <u>NCT 02676869</u>). Additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima's large pharmaceutical partners. Prima is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit <a href="https://www.primabiomed.com.au">www.primabiomed.com.au</a>.

# For further information please contact:

### **U.S. Investors:**

Matthew Beck, The Trout Group LLC +1 (646) 378-2933; <a href="mailto:mbeck@troutgroup.com">mbeck@troutgroup.com</a>

## **Australian Investors/Media:**

Mr Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; mgregorowski@citadelmagnus.com